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Clarence Chant1,2, Ann Leung1 and Jan O Friedrich2,3,4*Abstract
Introduction: The aim of this study was to determine whether using pharmacodynamic-based dosing of antimicrobials,
such as extended/continuous infusions, in critically ill patients is associated with improved outcomes as compared with
traditional dosing methods.
Methods: We searched Medline, HealthStar, EMBASE, Cochrane Clinical Trial Registry, and CINAHL from inception to
September 2013 without language restrictions for studies comparing the use of extended/continuous infusions with
traditional dosing. Two authors independently selected studies, extracted data on methodology and outcomes, and
performed quality assessment. Meta-analyses were performed by using random-effects models.
Results: Of 1,319 citations, 13 randomized controlled trials (RCTs) (n = 782 patients) and 13 cohort studies (n = 2,117
patients) met the inclusion criteria. Compared with traditional non-pharmacodynamic-based dosing, RCTs of continuous/
extended infusions significantly reduced clinical failure rates (relative risk (RR) 0.68; 95% confidence interval (CI) 0.49 to
0.94, P = 0.02) and intensive care unit length of stay (mean difference, −1.5; 95% CI, −2.8 to −0.2 days, P = 0.02), but not
mortality (RR, 0.87; 95% CI, 0.64 to 1.19; P = 0.38). No significant between-trial heterogeneity was found for these analyses
(I2 = 0). Reduced mortality rates almost achieved statistical significance when the results of all included studies (RCTs and
cohort studies) were pooled (RR, 0.83; 95% CI, 0.69 to 1.00; P = 0.054).
Conclusions: Pooled results from small RCTs suggest reduced clinical failure rates and intensive care unit length-of-stay
when using continuous/extended infusions of antibiotics in critically ill patients. Reduced mortality rates almost achieved
statistical significance when the results of RCTs were combined with cohort studies. These results support the conduct of
adequately powered RCTs to define better the utility of continuous/extended infusions in the era of antibiotic resistance.Introduction
Optimal use of antimicrobials is crucial in the critical
care setting, especially in an era of increasing antibiotic
resistance and lack of new antimicrobial development
[1]. Interest is growing in alternative antimicrobial dos-
ing strategies that are better aligned with the antimicro-
bial’s pharmacodynamic properties, and the potential of
this approach to improve patient outcomes [2]. Given
the highly variable and often unknown pharmacokinetics
of antimicrobials in critically ill patients as compared
with other hospitalized patients, alignment with the* Correspondence: j.friedrich@utoronto.ca
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reproduction in any medium, provided the orpharmacodynamics (PDs) of the antimicrobials is even
more important [3]. Antimicrobial pharmacodynamics
refers to the effects of a drug on microorganisms in rela-
tion to the drug’s concentration within the body (that is,
pharmacokinetics, PCKs). The PD of beta-lactam anti-
microbials (for example, penicillins, cephalosporins) are
termed time-dependent, as their effects are best correlated
with the amount of time that the serum concentrations
of the antimicrobial are above the minimum inhibitory
concentration (MIC) of the microorganism. Other anti-
biotics, such as fluoroquinolones and aminoglycosides,
have PD properties termed concentration-dependent
killing, given that their effects correlate best with
peak concentration/MIC ratio and/or area under the
concentration-time curve/MIC ratio [3]. To maximize
microorganism eradication, several dosing methods thattd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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investigated. These include administration of time-
dependent antimicrobials via extended (for example,
over a period of 3 to 4 hours) or continuous infusion, as
compared with traditional intermittent infusions (for
example, over a period of 30 minutes), or altering doses
based on both patient-specific pharmacokinetic parame-
ters and the MIC of the target organism (also known as
dual individualization) [3,4].
Unless clinical benefits are compelling, widespread
clinical application of pharmacodynamics-based dosing
(PDD) is unlikely, given the multitude of barriers to their
implementation. These barriers include (a) identification
of the types of patients that would benefit the most, with
the critically ill patient population being the most obvi-
ous choice, given their heightened risk of infectious-
related morbidity and mortality and increasing resist-
ance; (b) requirement of significant practice changes in
microbiology, such as routine MIC determination by
using more accurate nonautomated techniques; (c)
better-defined pharmacokinetics of antimicrobials in pa-
tients in the intensive care unit (ICU) with varyingFigure 1 Flow chart of study selection.degrees of renal and hepatic dysfunction, as well as the
extent of medication removal by a variety of renal-
replacement therapies; and (d) methods to manage the
need of a dedicated intravenous line for administration
via continuous/extended infusions. To justify such
changes, results of rigorously conducted and adequately
powered RCTs in a population most likely to benefit (for
instance, ICU patients) are needed, the design of which
should be informed by comprehensive systematic review
of current evidence. Previous systematic reviews that in-
cluded both critically ill and non-critically ill patient
populations have provided inconsistent results [5-7].
Therefore, to better define the current state of know-
ledge on this important topic and to update previously
reported systematic reviews, we conducted a systematic
review and meta-analysis comparing PD antimicrobial
dosing with traditional non-PDD on clinical outcomes
(mortality, clinical failure rates, and length-of-stay
(LOS)) focusing on critically ill patients. We included
both randomized and cohort studies but emphasized
the results of the RCTs in the interpretation of the
results.or Monte Carlo simulation 
Table 1 Characteristics of selected studies for meta-analysis




Infection Illness acuity Study antibiotic Control group Intervention group
APACHE II SAPS II
Randomized controlled trials
Georges (1999) France [12] NR RCT Pneumonia or bacteremia
with gram-negative bacilli
47 Cefepime 2 g q12h 4 g/d as CI
Hanes (2000) USA [13] T RCT Nosocomial pneumonia 12 Ceftazidime 2 g q8h (0.5-h infusion) LD, 2 g (0.5-h infusion), then
60 mg/kg/day as CI
Nicolau (2001) USA [14] MS, N RCT VAP 15 Ceftazidime 2 g q8h (0.5-h infusion) No LD 3 g over 24 h as CI
Wysocki (2001) France [15] MS RCT Any methicillin-resistant
staphylococcal infections
b Vancomycin 15 mg/kg q12h (1-h infusion) LD, 15 mg/kg over 1 h, then
30 mg/kg as CI
Bujik (2002) Netherlands [16] S RCT (partial) Severe intraabdominal infection 15 Ceftazidime 1.5 g tid (20-min infusion) LD, 1 g over 20 min, then
4.5 g/d as CI
Georges (2005) France [17] M, T RCT Nosocomial pneumonia
or bacteremia
45 Cefepime 2 g q12h (0.5-h infusion) No LD; 4 g CI
Rafati (2006) Iran [18] General RCT Sepsis from any source 15 Piperacillin alone 3 g q6h (0.5-h infusion) LD, 2 g over 0.5 h, then
8 g/24 h as CI
Roberts (2007) Australia [19] General RCT Sepsis from any source 18 Ceftriaxone LD= 500 mg, then 2 g q24h LD, 500 mg, then 2 g/24 h
as CI
Sakka (2007) Germany [20] NR RCT Nosocomial pneumonia 27 44 Imipenem 1 g q8h (40-min infusion) LD, 1 g over 40 min, then
2 g/24 hr as CI for 3 days,
then 1 g q8h over 40 min
Adembri (2008) Italy [21] M, T RCT Sepsis; glycopeptide resistant
or failure
45 Linezolid 600 mg q12h (0.5-h infusion) LD, 300 mg, Day 1: 900 mg CI,
Day 2 onward: 1,200 mg CI
Wang (2009) China [32] NR RCT Acinetobacter pneumonia 19 Meropenem 1 g q8h (1-h infusion) 500 mg q6h as 3-h EI
Chytra (2012) Czech [22] M RCT Severe infection from
any source
22 Meropenem 2 g q8h (0.5-h infusion) LD, 2 g over 0.5 h, then 4 g/d
as CI
Dulhunty (2012) Australia [29] NR RCT Severe sepsis 22 Ticarcillin/clavulanate,
piperacillin/tazobactam,
or meropenem
Dose determined by MD Dose determined by MD
All as intermittent infusion All as CI
Cohort studies
Schentag (1984) USA [23] NR Cohort Gram-negative nosocomial
pneumonia
NR Cefmenoxime Fixed dose 1–2 g q6-8 h Integration of patient-specific
PCK with bacteria-specific
killing kinetics (doses ranged
from 0.5 g q8h to 2 g q4h)
Lorente (2006) Spain [24] MS Cohort VAP with gram-negative
bacilli
15 Meropenem 1 g q6h (0.5-h infusion) LD, 1 g over 0.5 h, then
1 g q6h as CI
Itabashi (2007) Japan [33] NR Cohort Gram-negative pneumonia NR Meropenem 500 mg q12h (0.5- to 1-h
infusion)
500 mg q12 as 4-h EI
Lodise (2007) USA [25] NR Cohort Pseudomonal infections of
any source
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Lorente (2007) Spain [26] MS Cohort VAP with gram-negative
bacilli
16 Ceftazidime 2 g q12h (0.5-h infusion) LD, 1 g over 0.5 h, then
2 g q12h as CI
Lorente (2009) Spain [31] MS Cohort VAP with gram-negative
bacilli
16 Piperacillin/tazobactam 4.5 g q6h (0.5-h infusion) LD, 4.5 g over 0.5 h, then
4.5 g q6h as CI
Nicasio (2010) USA [27] MS, N Cohort VAP 19 Cefepime, or meropenem MD discretion (0.5 h-infusions)a VAP pathway derived by local
MICs and PD analysis using
Monte Carlo simulations
(3-h infusions)
Dow (2011) USA [30] MS Cohort Any infection except CF 25 Piperacillin/tazobactam,
or meropenem
P/T 3.375 g q6h or Meropenem
500 mg q6h (0.5-h infusions)
P/T 3.375 g q8h as 4 h EI,
Meropenem 500 mg q6h
as 3-h EI




3.375 g q8h as 4-h EI
Akers (2012) USA [34] Burn Cohort Gram-positive bacteremia NR Vancomycin 1 g q8h (dose adjustment to achieve
trough levels 15–20 μg/ml)
3 g as CI (dose adjustment to
achieve steady-state levels
20–25 μg/ml)
Lee (2012) USA [35] NR Cohort Gram-negative infections NRd Piperacillin/tazobactam 2.25-4.5 g q6-8 h (0.5-h infusion) 3.375 g q8h as 4-h EI
Arnold (2013) USA [36] NR Cohort Gram-negative infections 20 Cefepime, meropenem, or
piperacillin/tazobactam
Cefepime 2 g q8h, meropenem
1 g q8h, piperacillin-tazobactam
4.5 g q6h (0.5-h infusions)
Same dose/medications as
3-h infusions
Hsaiky (2013) USA [37] NR Cohort Gram-negative infections 16 Doripenem 0.5 g q8h (1-h infusion) 0.5 g q8h (4-h infusion)
M, mixed; MS, medical surgical; T, trauma; C, coronary; CV, cardiovascular; N, neurosurgical; NR, not reported.
aPiperacillin/tazobactam used as 24 h infusions in control group and not used in the intervention group.
bOnly mean SAPS score [86] equal to 14 provided.
cOnly midpoint of range provided.
dMedian SOFA [87] score of 9.
APACHE II, mean or median acute physiology and chronic health evaluation II score of enrolled patients [88]; CI, continuous infusion; EI, extended infusion; LD, loading dose; MIC, minimum inhibitory concentration; PD,
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Data sources
With the assistance of a librarian, we systematically searched
MEDLINE, HealthStar, EMBASE, Cochrane Clinical Trials
Registry, and CINAHL electronically from inception (1948,
1967, 1974, 1966, and 1981, respectively) to September 24,
2013, by using the following key words: critical care, critical
illness, intensive care unit, specific names of antibacterial
agents, pharmacokinetic, pharmacodynamic, extended infu-
sion, continuous infusion, drug administration, and dual
individualization. Terms were “exploded” and combined by
using Boolean operators where appropriate [see Additional
file 1]. No language restrictions were applied. Reference lists
of selected articles and personal files were also searched for
relevant citations.
Study selection
Inclusion criteria for this meta-analysis were as follows:
(a) adult (older than 16 years) critically ill patients, (b)
intervention that compared PDD to aid in the determin-
ation of antibiotic dosage (that is, extended infusions,
continuous infusions, clinical pathway, and dual
individualization principle) with a control group that did
not use such dosing strategies by using either a random-
ized or nonrandomized study design; (c) reporting of









Georges (1999) France [12] 1 18 N NR
Hanes (2000) USA [13] 1 32 N NR
Nicolau (2001) USA [14] 1 41 N NR
Wysocki (2001) France [15] 10 160 N Y (consecuti
sealed opaq
envelopes)
Bujik (2002) Netherlands [16]a 1 18 N NR
Georges (2005) France [17] 1 50 N NR
Rafati (2006) Iran [18] 1 40 N NR
Roberts (2007) Australia [19] 1 57 N Y (sequentia
sealed enve
Sakka (2007) Germany [20] 1 20 N Y (sealed en
Adembri (2008) Italy [21] 1 16 N Y (closed en
Wang (2009) China [32] 1 30 N NR
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envelopes)
Y, Yes; N, No; NR, not reported; CI, continuous infusion; LoS, length of stay; ARF, acute ren
aPartial randomization: first six patients allocated to continuous-infusion group; next 12 pstay, clinical failure); and (d) any antibacterial whose PD
associated with optimal killing is the proportion of time
during dosing interval that is above the MIC of the
pathogenic organism. Studies were excluded if (a) <50%
of patients were admitted to an ICU defined by authors;
(b) <50% adult patients; (c) only Monte Carlo simulation
or mathematical modeling data were included; (d) no
clinical outcomes were reported; (e) data were published
only as an abstract; or (f ) different antibiotics were used
in the control/intervention groups. Citations were
screened in duplicate from the initial results of the
search strategy, while full-text review, also in duplicate,
was performed to determine eligibility when either
screening reviewer thought a citation potentially met in-
clusion criteria. Disagreements regarding inclusion were
reconciled by consensus.
Data extraction
A standardized data-abstraction form was designed be-
fore the conduct of the literature search. Two reviewers
(CC, JF) independently abstracted data from included
studies, including data on the publication (that is, year,
author, and country), type of ICU, patient population,
study design, interventions used (that is, antibiotic used,
method of dosing), and outcomes (that is, mortality,
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1 from control group)
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atients randomized to continuous infusion or intermittent administration groups.
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extracted because very few studies reported such data.
Risk of bias in RCTs (including blinding of participants,
method of sequence generation and allocation conceal-
ment, intention-to-treat analysis, early trial stopping for
efficacy before the planned enrollment was completed,
and loss to follow up) and cohort studies (including
retrospective versus prospective data collection, concur-
rent versus historical controls, and comparable baseline
characteristics of cases and controls) were assessed, with
disagreements resolved by consensus.
Data analysis
Our primary outcome was all-cause mortality in patients
whose infections were managed with PDD (intervention
group) as compared with those whose infections were
managed by antibiotic dosing that did not incorporate
both pharmacodynamic and pharmacokinetic informa-
tion (control group). Mortality was determined at ICU
discharge, hospital discharge, 90, 60, 30, 28, or 14 daysTable 3 Quality assessment of included cohort studies






Schentag (1984) USA [23] 1 32 Prospecti
Lorente (2006) Spain [24] 1 89 Retrospec
Itabashi (2007) Japan [33] 1 42 Prospecti
Lodise (2007) USA [25] 1 194 Retrospec
Lorente (2007) Spain [26] 1 121 Retrospec
Lorente (2009) Spain [31] 1 83 Retrospec
Nicasio (2010) USA [27] 1 (3 separate ICUs) 168 Prospecti
Dow (2011) USA [30] 1 121 Retrospec
Yost (2011) USA [28] 14 359 Retrospec
Akers (2012) USA [34] 1 171 Retrospec
Lee (2012) USA [35] 2 148 Retrospec
Arnold (2013) USA [36] 1 503 Prospecti
Hsaiky (2013) USA [37] 1 86 a Retrospec
aData from 86 critically ill patients of 200 enrolled hospitalized patients reported se
Y, Yes; N, No; NR, not reported; COPD, chronic obstructive pulmonary disease.after study enrolment (in descending order of prefer-
ence). Secondary outcomes were ICU and hospital LOS,
and clinical failure as defined by individual study authors
(for example, lack of clinical cure or improvement). Sep-
arate analyses were performed by using lack of clinical cure
alone. Only RCTs were included in the primary analysis,
and prespecified subgroup analyses were as follows: (a) by
type of study (that is, RCT and cohort studies); (b) by anti-
biotic type (for example, beta-lactam alone, carbapenem
alone, cephalosporin alone, piperacillin/tazobactam alone,
or others); and (c) by intervention (that is, extended infu-
sions and continuous infusions). All analyses were per-
formed by using Review Manager (RevMan version 5.2;
Cochrane Collaboration, Oxford, UK) and random effects
models, which incorporate between-trial heterogeneity and
give wider and more conservative confidence intervals
(CIs) when heterogeneity is present [8].
We assessed statistical heterogeneity among trials by
using I2, defined as the percentage of total variability
across studies attributable to heterogeneity rather thanive/
ctive
Concurrent control Comparable baseline
ve N (historical) NR
tive Y (physician discretion) Y
ve Y (physician discretion) Y
tive N (historical) Y
tive Y (physician discretion) Y
tive Y (physician discretion) Y
ve N (historical) Y (except fewer intervention
patients with liver disease)
tive N (historical) Y
tive Y (physician discretion) N (higher use of concomitant
aminoglycosides, pseudomonas
infections, and rates of positive
cultures from respiratory and
other sources in control patients)
tive Y (physician discretion) Y (except control group received ~10%
lower average dose)
tive N (historical) Y (except control group more
COPD patients, more concomitant
use of fluoroquinolones and
aminoglycosides, and longer
(~1 d) duration and higher (~13%)
cumulative dose of therapy)
ve N (historical) Y (except control group more COPD
patients, more endotracheal (versus
bronchoalveolar lavage) cultures, less
Hemophilus influenzae, and more
use of meropenem)
tive N (historical) Y (except control group had lower
proportion of patients with positive
blood cultures)
parately.
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49%), moderate (I2 = 50% to 74%), and high (I2 ≥ 75%) het-
erogeneity [9]. Relative risks (RRs) were used to pool bin-
ary mortality and clinical failure data, and weighted mean
differences (MDs) to pool continuous LOS data. Ranges
[10] and interquartile ranges [11] were converted to stand-
ard deviations by using previously published methods
where necessary. Differences between pooled RRs were
evaluated by using z tests. We considered (two-sided) P ≤
0.05 as significant and reported individual trial and sum-
mary results with 95% confidence intervals. To assess for
publication bias, we visually examined a funnel plot com-
paring effect measure for the primary outcome of mortal-
ity with study precision for evidence of asymmetry.
Results
Study selection
In total, 26 studies were included in this meta-analysis
[12-37]. The initial search strategy resulted in 1,319Figure 2 Effects of pharmacodynamic-based antibiotic dosing on ICU
unspecified (ICU or hospital) [18-21,27,28,31,33] mortality grouped by
shown as squares with lines, and pooled RRs with 95% CI, calculated by
subgroup, are shown as diamonds. The interaction P value, calculated b
and cohort studies, was not significant (P = 0.61). The pooled results for
by the more-prolonged hospital mortality for the studies that also provi
to 1.17; P = 0.34; I2 = 0%), or if the results of the partial RCT [16] were exc
I2 = 0%). Weight refers to the weighting of each individual study to the overa
controlled trial; RR, relative risk.citations, of which 69 were retrieved for full review and
21 met all inclusion criteria and no exclusion criteria
[12-28,34-37]. Review of reference lists of the selected
studies, other systematic reviews [5-7], and personal files
resulted in five additional studies being included [29-33]
(Figure 1). The majority of studies were excluded during
initial screening because they were Monte Carlo simula-
tion studies that did not involve patients, or were studies
that did not involve PDD. The 48 studies were excluded
after full review for the following reasons: lack of control
group or clinical outcomes [38-64], not discussing
pharmacodynamic-based dosing [65-74], Monte Carlo
simulations or mathematical modeling [75-81], duplicate
publications [82,83], and review articles [84,85].
Description of included studies
The characteristics of the studies included in the meta-
analysis are described in Table 1. The included studies are
international (Europe, 10, USA, 11, Asia, 3, Australia, 2)[15-17,22,29], hospital [30,34,36,37], 14-day [25], 30-day [35], or
RCT versus cohort studies. Individual study RRs with 95% CIs are
using random-effects models both overall and separately for each
y using a Z test, testing for subgroup differences between the RCT
the RCTs were essentially unchanged if ICU mortality was replaced
ded these data [22,29] (nine RCTs, 620 patients, RR, 0.86; 95% CI, 0.64
luded (eight RCTs, 602 patients; RR, 0.88; 95% CI, 0.64 to 1.21; P = 0.42,
ll pooled RR. CI, confidence interval; IV, inverse variance; RCT, randomized
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cal, trauma, mixed) diagnosed mainly with pneumonia (n
= 12). Most studies involved a single antibiotic (n = 22),
typically with beta-lactam (n = 13) or carbapenem class (n
= 6) or both (n = 4). Most used either continuous (n = 16)
or extended (n = 8) infusion interventions, whereas one
was a clinical pathway designed by using local antibiogram
and MIC information and another by using the dual-
individualization principle. Thirteen studies were RCTs,
and 13 were cohort studies, of which four were prospect-
ive, and nine, retrospective. All but two of the RCTs and
all but two of the non-RCTs were single center. Sample
size ranged from 16 to 240 patients for the RCTs and 32
to 503 for the cohort studies.
For the 13 RCTs, only one had the participants blinded
to study interventions, whereas six reported allocation
concealment, and four specified that analysis was by
intention-to-treat. Only three of the RCTs specifically re-
ported that losses to follow-up were <5% of randomized
patients.Figure 3 Effects of pharmacodynamic-based antibiotic dosing on clin
grouped by RCT versus cohort studies. Individual study RR with 95% CIs
calculated by using random-effects models both overall and separately for
subgroup differences. If clinical failure is defined only as lack of clinical cure
RCTs, 525 patients; RR, 0.83; 95% CI, 0.70 to 0.99; P = 0.04; I2 = 11%) and ove
I2 = 70%). Weight refers to the weighting of each individual study to the ov
randomized controlled trial; RR, relative risk.For the cohort studies, only four of the 13 were pro-
spective, and six studies used concurrent control groups.
Details regarding assessment of bias among individual
studies are outlined in Tables 2 and 3.
Morbidity and mortality
The 13 RCTs [12-22,29,32] included data from 782 pa-
tients, and the 13 cohort studies [23-28,30,31,33-37],
from 2,117 patients. Two studies [28,37] enrolling all
hospitalized patients reported mortality data separately
for patients requiring ICU admission. Reduction in mor-
tality (nine RCTs; n = 620; RR, 0.87; 95% CI, 0.64 to 1.19;
P = 0.38) almost achieved statistical significance when
the results of all included studies (RCTs and cohort
studies) were pooled (19 studies; n = 2,354; RR, 0.83;
95% CI, 0.69 to 1.00; P = 0.054) (Figure 2). Focusing the
pooled analysis on only RCTs, PDD significantly reduced
clinical failure rates, defined as either lack of clinical
cure or improvement (seven RCTs; n = 565; RR, 0.68;
95% confidence interval [CI], 0.49 to 0.94; P = 0.02)ical failure, defined as lack of clinical cure or improvement,
are shown as squares with lines, and pooled RRs with 95% CI,
each subgroup, are shown as diamonds. Z tests were used to test for
, results were identical for the non-RCTs and similar for the RCTs (seven
rall (14 studies, 1,509 patients; RR, 0.68; 95% CI, 0.52 to 0.88; P = 0.004;
erall pooled RR. CI, confidence interval; IV, inverse variance; RCT,
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ference, −1.5; 95% CI, -2.8 to −0.2 days; P = 0.02) (Figure 4).
There was no significant between-trial heterogeneity for
these analyses (I2 = 0). Incorporating pooled data from
non-RCTs also yielded significantly reduced clinical failure
rates but with increased heterogeneity (Figure 3). PDD did
not result in reduced hospital lengths of stay, but few stud-
ies reported this outcome (Figure 5). Visual inspection of
the funnel plot comparing the effect measure (RR) for the
primary outcome of mortality for each study with its
precision, expressed as the standard error of the natural
logarithm of RR, SE(log(RR)) did not suggest asymmetry
(see Additional file 2).
Subgroup analysis
Examining effects by types of antibiotics (Figure 6), only
studies involving piperacillin/tazobactam (or piperacillin
alone) clearly demonstrated a survival advantage for the
intervention group (five studies [18,25,28,31,35], n = 683;
RR, 0.62; 95% CI, 0.46 to 0.85; P = 0.003; I2 = 0%), although
only one of five studies in this subgroup was an RCT [18].
Studies involving carbapenems almost demonstrated aFigure 4 Effects of pharmacodynamic-based antibiotic dosing on ICU
study RRs with 95% CIs are shown as squares with lines, and pooled RRs w
and separately for each subgroup, are shown as diamonds. Z tests were us
standard deviations by dividing by 1.35, as previously described [11], or sta
standard deviations between groups [30]. Weight refers to the weighting o
IV, inverse variance; RCT, randomized controlled trial; SD, standard deviationsurvival advantage for the intervention group (four trials
[20,22,33,37]; n = 388; RR, 0.64; 95% CI, 0.41 to 1.00;
P = 0.051; I2 = 0%), with two of four studies being RCTs
[20,22]. With respect to type of intervention, extended in-
fusions, all of which were cohort studies, improved sur-
vival (eight studies [25,27,28,30,33,35-37]; n = 1,580; RR,
0.72; 95% CI, 0.54 to 0.96; P = 0.03; I2 = 42%). Improved
survival in the studies using continuous infusions did not
achieve statistical significance (nine RCTs [15-22,29] and
two cohort studies [31,34], n = 874; RR, 0.97; 95% CI, 0.76
to 1.25; P = 0.84; I2 = 0) (Figure 7).
Discussion
Pooled results from small RCTs suggest that PDD, by
using primarily continuous or extended infusions of an-
tibiotics, reduces clinical failure rates and ICU LOS in
critically ill patients when compared with traditional dos-
ing methods. Reduced mortality rates almost achieved
statistical significance when the results of RCTs were
combined with cohort studies.
Unlike previous meta-analyses, our systematic review
included only data from critically ill patients, stratifiedlength of stay, grouped by RCT versus cohort studies. Individual
ith 95% CI, calculated by using random-effects models both overall
ed to test for subgroup differences. IQR [22,29,35,36] converted to
ndard deviations calculated from reported 95% CIs, assuming equal
f each individual study to the overall pooled RR. CI, confidence interval;
; IQR, interquartile range.
Figure 5 Effects of pharmacodynamic-based antibiotic dosing on hospital length of stay, grouped by RCT versus cohort studies.
Individual study RRs with 95% CIs are shown as squares with lines, and pooled RRs with 95% CI, calculated by using random-effects models both
overall and separately for each subgroup, are shown as diamonds. Z tests were used to test for subgroup differences. Ranges [25] or IQR
[22,36,37] converted to standard deviations by using the methods of Hozo [10] or by dividing by 1.35, as previously described [11], respectively,
or standard deviations calculated from reported 95% confidence intervals assuming equal standard deviations between groups [30]. Weight refers
to the weighting of each individual study to the overall pooled RR. CI, confidence interval; IV, inverse variance; RCT, randomized controlled trial;
SD, standard deviation; IQR, interquartile range.
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ically used antibacterial agents, and a larger number of
studies. We were able to demonstrate a statistically sig-
nificant improvement in clinical outcomes (reduced clin-
ical failure rates) and ICU LOS, even when exclusively
methodologically more-rigorous RCT data are pooled.
Three previous meta-analyses, each with fewer studies,
included both critically ill and non-critically ill patients
and found somewhat different results. Two of these
meta-analyses found either no benefit [5,6] or that clin-
ical outcomes were improved only when the same dose
of antibiotic was given as continuous infusions when
compared with intermittent infusions [6]. Our more
comprehensive and updated search included all of the
RCTs in ICU found in previous systematic reviews plus
additional studies, which may have contributed to these
differences.
Similar to the most recent meta-analysis [7], we also
found that mortality improvement was seen with con-
tinuous/extended infusions of only piperacillin/tazobac-
tam and carbapenems in ICU patients, albeit largely
because of data from non-RCTs.
Our pooled results, at least among RCTs, were consist-
ent between studies. This lack of statistical heterogeneityoccurred despite significant differences between studies in
types of antibiotics used, interventions studied (that is, ex-
tended or continuous infusions, or other pharmacodynamic-
based dosing strategies), dosages of antibiotic used (that is,
whether both arms of the study received the same dose of
antibiotic, whether loading doses were given), types of organ-
isms or infections studied, and whether concomitant
pharmacokinetic data (that is, therapeutic drug moni-
toring) was also performed to validate the dosing strat-
egies. We found piperacillin/tazobactam to be the most
studied antibiotic, and the only one that resulted in a clear
improvement in mortality, albeit largely because of cohort
studies. In our study, extended infusions but not continu-
ous infusions demonstrated a statistically significant
reduction in mortality. This is inconsistent with the
theoretical background, given that extended infusions
may not result in serum antibiotic concentrations that
are above the minimum inhibitory concentration (MIC) of
the infecting pathogen throughout the entire dosing inter-
val, and our findings may be due to methodologic differ-
ences, given that all of the extended-infusion studies were
nonrandomized, whereas all but two of the continuous-
infusion studies were RCTs. However, although for an-
tibiotics such as beta-lactams and carbapenems, the
Figure 6 Effects of pharmacodynamic-based antibiotic dosing on mortality separated by class of antibiotic. Individual study RRs with 95%
CIs are shown as squares with lines, and pooled RRs with 95% CI, calculated by using random-effects models separately for each class of antibiotic, are shown
as diamonds. Weight refers to the weighting of each individual study to the overall pooled RR. CI, confidence interval; IV, inverse variance; RR, relative risk.
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http://ccforum.com/content/17/6/R279commonly accepted PD parameter associated with im-
proved cure rates are free drug concentration above
MIC for 40% to 70% of the dosing interval, these pa-
rameters have not been subjected to rigorous clinical
evaluation in multiple studies, and their validity was
recently challenged [90].
In addition, it is well known that pharmacokinetic pa-
rameters are highly variable in critically ill patients be-
cause of a variety of factors [91], and thus whether any
PD targets were actually attained by any interventions
should ideally be confirmed by using actual pharmacoki-
netic measurements in each individual study, to better
correlate with clinical and other end points. For ex-
ample, augmented renal clearance, seen in some critic-
ally ill sepsis and trauma patients [92], might lead to an
inability to achieve concentrations above the MICFigure 7 Effects of pharmacodynamic-based antibiotic dosing on mo
The continuous-infusion studies included nine RCTs [15-22,29] and two coh
only cohort studies. Individual-study RRs with 95% CIs are shown as square
random-effects models both overall and separately for each subgroup, are
test, testing for subgroup differences between continuous and extended in
refers to the weighting of each individual study to the overall pooled RR. C
trial; RR, relative risk.because of greater clearance in some patients, and this
would have a greater impact on continuous versus ex-
tended infusions.
As evident from the list of studies included in this
meta-analysis, PDD strategies are not a new concept. In-
deed, the concept of dual-individualization incorporating
both patient PCK and bacterial PD information to arrive
at dosage regimen dates back to the 1980s [23]. Even the
concept of extended or continuous infusions would
benefit from individualization by using patient-specific
PCK parameters and organism-specific MIC to verify
that these infusions did indeed reach the PD target.
Given the intense resources required for such an inter-
vention (that is, infrequently reported PCK of antibiotics
in ICU patients, or bacteria-specific MIC for each infec-
tion), this concept has not been universally adopted.rtality comparing continuous with extended-infusion subgroups.
ort studies [31,34], whereas the extended-infusion studies included
s with lines, and pooled RRs with 95% CIs, calculated by using
shown as diamonds. The interaction P value, calculated by using a Z
fusion studies, did not achieve statistical significance (P = 0.12). Weight
I, confidence interval; IV, inverse variance; RCT, randomized controlled
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http://ccforum.com/content/17/6/R279More recently, given the increase in bacterial resistance
and dearth of new antibiotics, significant attention has
been paid to optimizing use of currently existing antibi-
otics through, for example, extended/continuous infu-
sions. Practically speaking, it is still not an accepted
standard of practice for all institutions to report MICs
for all organisms despite having these MICs determined
by automated systems because of errors associated with
automated techniques, and there are still a large number
of unknowns when it comes to PCK parameters in ICU
patients. Therefore to translate the knowledge truly from
the plethora of in vitro / Monte Carlo-type studies to ac-
tual ICU patients, significant system changes and further
research, as previously outlined, must occur. This sys-
tematic review of primarily small, single-center studies
of critically ill patients, a patient population that is most
likely to benefit because of their severity of illness and
increased potential for infections with more-resistant or-
ganisms, suggests that PDD may lead to improved
patient-centered clinical outcomes and supports the
conduct of more adequately powered and rigorously per-
formed RCTs to confirm these findings.
The strengths of our study include the use of rigorous
systematic review and meta-analytic methods consistent
with PRISMA guidelines [93], including a reproducible
and comprehensive literature-search strategy without
language restrictions, clearly defined inclusion criteria,
duplicate citation review, data abstraction, and quality
assessment of individual studies, and a predefined
statistical-analysis plan. Our meta-analysis also included
more studies of critically ill patients: previous meta-
analyses included only five to seven studies enrolling pri-
marily critically ill patients, of which only two to six
were RCTs [5-7], whereas our meta-analysis included 26
studies enrolling primarily critically ill patients, of which
13 were RCTs.
Our study also has limitations. The numbers of pa-
tients enrolled in the selected studies were relatively
small, and most of the RCTs were unblinded and single
center, with only a minority reporting on quality indica-
tors, such as allocation concealment, intention-to-treat
analysis, and losses to follow-up after randomization.
This makes further subgroup analysis not useful, given
the small sample size in each study and the types of
studies. To be comprehensive, we included all antibacte-
rials, all study types, and all dosages of antibiotics and
also studies targeting different PD end points, which re-
sulted in clinical heterogeneity among included studies.
Surprisingly, the pooled results, at least among RCTs,
demonstrated no statistical heterogeneity; however, tests
for heterogeneity have lower statistical power when the
number of trials is small. Clinical cure is a subjective
outcome that was defined by each study’s authors, and
potentially subject to bias, given that the studies weremainly unblinded [94], and the microbiologic causes of
infections were different, and appropriateness of empiric
antibiotics, a key determinant of outcomes, was not re-
ported. Even a moderately sized additional RCT could
negate the statistically significant improvement in this
outcome. For example, a recently completed blinded
placebo-controlled RCT in critically ill patients with
ventilator-associated pneumonia [95], which did not
meet our inclusion criteria because it compared two dif-
ferent antibiotics for different durations of therapy (ex-
tended (4-hour) dose doripenem for 7 days versus
intermittent dose imipenem/cilastatin for 10 days),
found higher clinical failure rates in the extended-dose
doripenem group (43/79 (54%) versus 38/88 (43%)).
Adding data from this trial to our pooled result would
make the improved clinical failure rates among the
continuous/extended RCTs no longer statistically sig-
nificant: eight RCTs, n = 732; RR, 0.81; 95% CI, 0.57 to 1.15;
P = 0.24. It would also eliminate statistically significant mor-
tality improvements in the subgroup of extended-infusion
cohort studies, and the subgroup of carbapenem studies.
In addition, almost all studies included in this
review permitted the use of concomitant antibiotics
[12,14-19,21,22,24-31,34-37], whereas the remainder
did not specifically report on whether their use was
permitted [13,20,23,32,33]. This use of concomitant
antibiotics may have contributed to reduced differ-
ences in outcomes between groups. We also did not
conduct our analysis controlling for differences in
antibacterial dosing regimens (for example, with or
without loading doses) or patient severity of illness.
The latter would require patient-level data that would
be challenging to acquire.
Conclusions
In conclusion, pooled results from small RCTs suggest
that PDD reduces clinical failure rates and ICU LOS in
critically ill patients, and may reduce mortality rates
when the results of RCTs are combined with cohort
studies. Given the limitations of our review, these find-
ings support the conduct of future adequately powered
and well-designed RCTs to confirm these findings for
this important clinical question.
Key messages
 Pooled analysis of randomized controlled trials
suggests that continuous/extended infusions of
antibiotics in critically ill patients improve cure
rates, length of stay, and possibly mortality.
 This study adds to the current body of literature by
focusing on critically ill patients and including a
larger number of studies without restriction on type
of antibiotics.
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